INNATE PHARMA SA (IPH.PA) Stock Fundamental Analysis

EPA:IPH • FR0010331421

1.49 EUR
+0.08 (+5.97%)
Last: Feb 24, 2026, 05:28 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

IPH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 77 industry peers in the Biotechnology industry. IPH has a bad profitability rating. Also its financial health evaluation is rather negative. IPH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year IPH has reported negative net income.
  • IPH had a negative operating cash flow in the past year.
  • IPH had negative earnings in each of the past 5 years.
  • IPH had a negative operating cash flow in each of the past 5 years.
IPH.PA Yearly Net Income VS EBIT VS OCF VS FCFIPH.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • IPH's Return On Assets of -49.55% is on the low side compared to the rest of the industry. IPH is outperformed by 61.04% of its industry peers.
  • IPH has a Return On Equity of -895.24%. This is in the lower half of the industry: IPH underperforms 66.23% of its industry peers.
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROIC N/A
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IPH.PA Yearly ROA, ROE, ROICIPH.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

  • IPH has a Gross Margin (49.52%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of IPH has declined.
  • IPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
IPH.PA Yearly Profit, Operating, Gross MarginsIPH.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • IPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IPH has been increased compared to 1 year ago.
  • The number of shares outstanding for IPH has been increased compared to 5 years ago.
  • IPH has a better debt/assets ratio than last year.
IPH.PA Yearly Shares OutstandingIPH.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPH.PA Yearly Total Debt VS Total AssetsIPH.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • IPH has an Altman-Z score of -6.50. This is a bad value and indicates that IPH is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -6.50, IPH is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 3.52 is on the high side and indicates that IPH has dependencies on debt financing.
  • With a Debt to Equity ratio value of 3.52, IPH is not doing good in the industry: 62.34% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.52
Debt/FCF N/A
Altman-Z -6.5
ROIC/WACCN/A
WACC6.85%
IPH.PA Yearly LT Debt VS Equity VS FCFIPH.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • IPH has a Current Ratio of 2.21. This indicates that IPH is financially healthy and has no problem in meeting its short term obligations.
  • IPH has a Current ratio of 2.21. This is comparable to the rest of the industry: IPH outperforms 46.75% of its industry peers.
  • A Quick Ratio of 2.21 indicates that IPH has no problem at all paying its short term obligations.
  • The Quick ratio of IPH (2.21) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 2.21
IPH.PA Yearly Current Assets VS Current LiabilitesIPH.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • IPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.42%.
  • Looking at the last year, IPH shows a very negative growth in Revenue. The Revenue has decreased by -75.86% in the last year.
  • The Revenue for IPH have been decreasing by -28.80% on average. This is quite bad
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%

3.2 Future

  • Based on estimates for the next years, IPH will show a very negative growth in Earnings Per Share. The EPS will decrease by -19.15% on average per year.
  • Based on estimates for the next years, IPH will show a very strong growth in Revenue. The Revenue will grow by 41.95% on average per year.
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue Next Year-26.21%
Revenue Next 2Y3.05%
Revenue Next 3Y2.41%
Revenue Next 5Y41.95%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IPH.PA Yearly Revenue VS EstimatesIPH.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
IPH.PA Yearly EPS VS EstimatesIPH.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • IPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPH.PA Price Earnings VS Forward Price EarningsIPH.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPH.PA Per share dataIPH.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • IPH's earnings are expected to decrease with -19.15% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • IPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INNATE PHARMA SA

EPA:IPH (2/24/2026, 5:28:32 PM)

1.49

+0.08 (+5.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-26
Inst Owners9.46%
Inst Owner ChangeN/A
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap139.62M
Revenue(TTM)6.00M
Net Income(TTM)-46.05M
Analysts82.5
Price Target6.27 (320.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.27
P/FCF N/A
P/OCF N/A
P/B 27.14
P/tB 27.14
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.06
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.52%
FCFM N/A
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 3.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.84%
Cap/Sales 2.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 2.21
Altman-Z -6.5
F-Score2
WACC6.85%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%
Revenue Next Year-26.21%
Revenue Next 2Y3.05%
Revenue Next 3Y2.41%
Revenue Next 5Y41.95%
EBIT growth 1Y-31.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.86%
EBIT Next 3Y68.81%
EBIT Next 5YN/A
FCF growth 1Y-27.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.01%
OCF growth 3YN/A
OCF growth 5YN/A

INNATE PHARMA SA / IPH.PA FAQ

Can you provide the ChartMill fundamental rating for INNATE PHARMA SA?

ChartMill assigns a fundamental rating of 2 / 10 to IPH.PA.


What is the valuation status for IPH stock?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA (IPH.PA). This can be considered as Overvalued.


How profitable is INNATE PHARMA SA (IPH.PA) stock?

INNATE PHARMA SA (IPH.PA) has a profitability rating of 0 / 10.